Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2014; 20(27): 9170-9177
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9170
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9170
Table 1 Baseline characteristics of the patients enrolled n (%)
| Baseline characteristics | Ulcerative colitis | Crohn’s disease | P |
| (n = 38) | (n = 59) | ||
| Sex | |||
| Men | 16 (42.1) | 33 (55.9) | 0.184 |
| Women | 22 (57.9) | 26 (44.1) | |
| Age (mean ± SD, yr) | 41.9 (14.2) | 38.9 (38.9) | 0.312 |
| Duration of disease [median (interquartile range), yr] | 4.5 (2-10.3) | 6 (1-12) | 0.738 |
| Smoking status | |||
| Non-smoker | 15 (39.5) | 21 (35.6) | 0.003 |
| Smoker | 8 (21.1) | 30 (50.8) | |
| Ex-smoker | 15 (39.5) | 8 (13.6) | |
| Steroid status | |||
| Neither steroid dependent nor refractory | 0 | 19 (32.2) | < 0.001 |
| Steroid dependent | 21 (55.3) | 33 (55.9) | |
| Steroid refractory | 17 (44.7) | 7 (11.9) | |
| Steroid use at induction | |||
| No | 10 (26.3) | 38 (64.4) | < 0.001 |
| Yes | 28 (73.7) | 21 (35.6) | |
| Immunomodulator therapy | |||
| No | 7 (18.4) | 14 (23.7) | 0.536 |
| Yes | 31 (81.6) | 45 (76.3) |
- Citation: Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014; 20(27): 9170-9177
- URL: https://www.wjgnet.com/1007-9327/full/v20/i27/9170.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i27.9170